Egetis Therapeutics AB (publ) (STO:EGTX)

Market Cap	2.32B +75.6%
Revenue (ttm)	62.40M +35.4%
Net Income	-342.50M
EPS	-0.93
Shares Out	395.16M
PE Ratio	n/a
Forward PE	13.26
Dividend	n/a
Ex-Dividend Date	n/a

Volume	360,445
Average Volume	831,052
Open	5.86
Previous Close	5.86
Day's Range	5.72 - 5.87
52-Week Range	3.03 - 7.07
Beta	0.78
RSI	57.12
Earnings Date	Apr 29, 2026

About Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 40
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EGTX

Financial Performance

In 2025, Egetis Therapeutics AB's revenue was 62.40 million, an increase of 35.36% compared to the previous year's 46.10 million. Losses were -342.50 million, -0.32% less than in 2024.